Amanda J. Oliver
YOU?
Author Swipe
View article: GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease
GZMK+CD8+ T cells target a specific acinar cell type in Sjögren's disease Open
Using single-cell and spatial transcriptomics and proteomics, this study identifies a selective loss of PRR4⁺CST3⁺WFDC2⁻ seromucous acinar cells and a rise in GZMK⁺CD8⁺ T cells in Sjögren's disease, revealing distinct immune-mediated epith…
View article: An atlas of TF driven gene programs across human cells
An atlas of TF driven gene programs across human cells Open
Combinations of transcription factors (TFs) regulate gene expression and determine cell fate. Much effort has been devoted to understanding TF activity in different tissues and how tissue-specificity is achieved. However, ultimately gene r…
View article: An organotypic atlas of human vascular cells
An organotypic atlas of human vascular cells Open
The human vascular system, comprising endothelial cells (ECs) and mural cells, covers a vast surface area in the body, providing a critical interface between blood and tissue environments. Functional differences exist across specific vascu…
View article: Single Cell Integration Characterises Metaplasia in Inflammatory Intestinal Diseases
Single Cell Integration Characterises Metaplasia in Inflammatory Intestinal Diseases Open
The gastrointestinal (GI) tract consists of connected organs, from the oral cavity to rectum, which function to ensure efficient nutrient uptake and barrier immunity. Diseases of the GI tract affect millions worldwide and as such there are…
View article: Gene-level alignment of single-cell trajectories
Gene-level alignment of single-cell trajectories Open
Single-cell data analysis can infer dynamic changes in cell populations, for example across time, space or in response to perturbation, thus deriving pseudotime trajectories. Current approaches comparing trajectories often use dynamic prog…
View article: GZMK+CD8+ T cells Target A Specific Acinar Cell Type in Sjögren’s Disease
GZMK+CD8+ T cells Target A Specific Acinar Cell Type in Sjögren’s Disease Open
Sjögren's Disease (SjD) is a systemic autoimmune disease without a clear etiology or effective therapy. Utilizing unbiased single-cell and spatial transcriptomics to analyze human minor salivary glands in health and disease we developed a …
View article: Ecological Model to Evaluate Borrow Areas in the Lower Mississippi River
Ecological Model to Evaluate Borrow Areas in the Lower Mississippi River Open
An aquatic analysis of constructing borrow areas adjacent to the main line levees in the Lower Mississippi River was conducted as part of an Environmental Impact Statement for upgrading the levee system. A Habitat Suitability Index (HSI) r…
View article: Early human lung immune cell development and its role in epithelial cell fate
Early human lung immune cell development and its role in epithelial cell fate Open
Studies of human lung development have focused on epithelial and mesenchymal cell types and function, but much less is known about the developing lung immune cells, even though the airways are a major site of mucosal immunity after birth. …
View article: Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis
Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis Open
Despite the overwhelming evidence that multiple sclerosis is an autoimmune disease, relatively little is known about the precise nature of the immune dysregulation underlying the development of the disease. Reasoning that the CSF from pati…
View article: An integrated cell atlas of the lung in health and disease
An integrated cell atlas of the lung in health and disease Open
Single-cell technologies have transformed our understanding of human tissues. Yet, studies typically capture only a limited number of donors and disagree on cell type definitions. Integrating many single-cell datasets can address these lim…
View article: Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combin…
View article: Supplementary Figures from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Supplementary Figures from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Supplementary Figures S1-S5
View article: Supplementary Figures from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Supplementary Figures from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Supplementary Figures S1-S5
View article: Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Data from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring a BRAFV600 mutation. While this triple therapy has potent tumor-intrinsic effects, the impact of this combin…
View article: Supplementary Table S1 from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Supplementary Table S1 from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Supplementary Table S1
View article: Supplementary Table S1 from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
Supplementary Table S1 from Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma Open
Supplementary Table S1
View article: Supplementary Figure Legends from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Supplementary Figure Legends from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Supplementary Figure Legends
View article: Figure S2 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S2 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S2 shows the expression of chemokines following single agent anti-PD-1 therapy in patients and their association with patient prognosis and immune cell infiltrate.
View article: Figure S4 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S4 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S4 shows the effect of CXCR3 blockade on the number and phenotype of tumor-infiltrating immune cells post combination therapy
View article: Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Data from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Purpose:In this article, we describe a combination chimeric antigen receptor (CAR) T-cell therapy that eradicated the majority of tumors in two immunocompetent murine pancreatic cancer models and a human pancreatic cancer xenograft model.E…
View article: Supplementary Figure 1 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 1 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 1. Panc02-Her2, KPC-Her2 and 24JK-Her2 cells express comparable levels of Her2.
View article: Figure S1 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S1 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S1 shows the response of AT-3 ova tumors to single agent anti-PD-1 or anti-CTLA-4 and the upregulation of chemokine receptors or chemokines following dual or single agent therapy.
View article: Supplementary Figure 8 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 8 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 8. Proposed mechanisms and clinical application for the ACTIV+Pano treatment.
View article: Figure S7 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S7 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S7 shows the gene expression profile of macrophages and other immune cell subsets in cancer patients
View article: Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Supplementary Figure 4 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer Open
Supplementary Figure 4. Pano did not enhance the cytotoxicity of CARaMEL cells nor oncolysis of VV-gp100.
View article: Figure S6 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S6 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S6 shows the phenotype and expression of CXCL9 and CXCL10 by tumor-infiltrating immune cells following treatment with anti-PD-1 and anti-CTLA-4
View article: Figure S5 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Figure S5 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Open
Figure S5 shows the expression of CXCL9 and CXCL10 mRNA and protein by AT-3ova tumor cells following stimulation with IFNgamma and TNFalpha